➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Johnson and Johnson
Colorcon
Medtronic
Moodys

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MAXALT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Maxalt

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00360282 ↗ Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Completed Merck Sharp & Dohme Corp. N/A 2006-08-01 The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
NCT00360282 ↗ Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Completed University of Pittsburgh N/A 2006-08-01 The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
NCT00397254 ↗ Two Rizatriptan Prescribing Portions for Treatment of Migraine Completed Merck Sharp & Dohme Corp. Phase 4 2006-12-01 The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
NCT00397254 ↗ Two Rizatriptan Prescribing Portions for Treatment of Migraine Completed Clinvest Phase 4 2006-12-01 The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
NCT00471952 ↗ Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed Merck Sharp & Dohme Corp. Phase 3 2007-04-01 The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Maxalt

Condition Name

Condition Name for Maxalt
Intervention Trials
Migraine 2
Migraine With Aura 1
Chronic Post-traumatic Headache 1
Vestibular Migraine 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Maxalt
Intervention Trials
Migraine Disorders 5
Headache 2
Migraine with Aura 1
Motion Sickness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Maxalt

Trials by Country

Trials by Country for Maxalt
Location Trials
United States 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Maxalt
Location Trials
California 2
Pennsylvania 2
Minnesota 1
Washington 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Maxalt

Clinical Trial Phase

Clinical Trial Phase for Maxalt
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Maxalt
Clinical Trial Phase Trials
Completed 4
Recruiting 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Maxalt

Sponsor Name

Sponsor Name for Maxalt
Sponsor Trials
Merck Sharp & Dohme Corp. 5
Diamond Headache Clinic 1
Clinvest 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Maxalt
Sponsor Trials
Other 5
Industry 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Dow
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.